Further, ERBB2 mutations, NRG1 fusions, EGFR exon 20 insertions, NTRK rearrangements, and tumor molecular burden (TMB) could be promising targets in lung cancer and could be implemented in the test panels [1]. This evidence concerns the gene EGFR and neoplasm.